Align Technology (NASDAQ:ALGN) Stock Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Align Technology, Inc. NASDAQ: ALGN. In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Align Technology stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
• Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
• Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.

Align Technology Trading Up 2.8 %

Align Technology stock traded up $4.48 during mid-day trading on Wednesday, hitting $162.56. The company had a trading volume of 198,561 shares, compared to its average volume of 829,741. The company has a market capitalization of $11.96 billion, a price-to-earnings ratio of 28.91, a P/E/G ratio of 2.24 and a beta of 1.69. Align Technology, Inc. has a 12-month low of $153.77 and a 12-month high of $331.64. The company's fifty day moving average is $191.02 and its 200-day moving average is $213.38.

Remove Ads

Align Technology (NASDAQ:ALGN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.96 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.43 by ($0.47). Align Technology had a return on equity of 13.84% and a net margin of 10.54%. As a group, sell-side analysts expect that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Align Technology

Hedge funds have recently made changes to their positions in the business. True Wealth Design LLC lifted its holdings in shares of Align Technology by 10,700.0% in the 3rd quarter. True Wealth Design LLC now owns 108 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 107 shares during the period. Picton Mahoney Asset Management boosted its position in shares of Align Technology by 69.9% during the 4th quarter. Picton Mahoney Asset Management now owns 141 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 58 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new position in shares of Align Technology in the 4th quarter valued at about $31,000. Neo Ivy Capital Management acquired a new stake in shares of Align Technology in the third quarter valued at about $32,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Align Technology in the 4th quarter valued at approximately $35,000. Institutional investors and hedge funds own 88.43% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Morgan Stanley reduced their target price on Align Technology from $280.00 to $272.00 and set an "overweight" rating for the company in a report on Thursday, February 6th. Wells Fargo & Company initiated coverage on shares of Align Technology in a research note on Friday, February 14th. They issued an "overweight" rating and a $255.00 price target for the company. Jefferies Financial Group decreased their price objective on Align Technology from $285.00 to $260.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Needham & Company LLC reiterated a "hold" rating on shares of Align Technology in a research report on Thursday, February 6th. Finally, Leerink Partners upgraded Align Technology from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $235.00 to $280.00 in a research report on Monday, January 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $262.64.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.